珍寶島(603567.SH):一種穿心蓮內酯改構化合物的鹽型、晶型 及其製備方法獲得專利授權證書
格隆匯8月14日丨珍寶島(603567.SH)公佈,公司收到歐洲專利局頒發的《專利授權證書》,穿心蓮內酯改構化合物為炎症和纖維化相關通路抑制劑,它對炎症和纖維化通路h1(IL-2,IL-6和TNF-α)、Th2(IL-13)和TGF-β1抑制作用明顯,對所測試的其它24個激酶均無抑制和誘導作用。體內研究表明,本品在治療性大鼠IPF模型中顯示出對肺部炎症和纖維化的顯著改善作用,且明顯優於作用機制類似的吡非尼酮;在預防性大鼠IPF模型中也顯示出對肺部炎症和纖維化的顯著改善作用。本品擬用於特發性肺纖維化(IPF)的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.